Treatment for peanut allergy

Abstract

The present invention relates to oral immunotherapy for the desensitisation of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2mg, 5mg, 12.5mg, 25mg, 50mg, 0mg, 200mg, 400mg and 800mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years.

Description

technical field [0001] The present invention relates to the treatment of peanut allergy by oral immunotherapy (OIT). Background technique [0002] Peanut allergy is common, affecting 1 to 2 percent of young children in Europe and the United States [1-3], unlike other common childhood food allergies (eg, egg allergy), resolution of which is less common[ 4]. The quality of life of affected families is reduced by the constant fear of food choices and the possibility of allergic reactions [5, 6]. Families of children with peanut allergy are poorly informed about how to avoid and treat food allergy emergency visits despite the best available treatments [7]. Unintended reactions are common (annual incidences of 3%, 14%, and 50% have been reported in numerous studies [8]). Nearly one-third of children with nut allergies are unaware that they are allergic to the nut—a lack of awareness that puts them at increased risk of inadvertent ingestion [9]. Therefore, it is necessary to d...

AI Technical Summary

Problems solved by technology

Nearly a third of children with nut allergies are unaware that they are allergic to the nut - a lack of awareness that puts them at increased risk of inadvertent ingestion [9]

Images